Gaviscon Double Action Mint Chewable Tablets 48pk

Specifications

About this product

This medicinal product contains 223.56 mg (9.72 mmol) sodium per 4 tablet dose, equivalent to 11.18 % of the WHO recommended maximum daily intake for sodium. The maximum daily dose of this product is equivalent to 44.71% of the WHO recommended maximum daily intake for sodium. This product is considered high in sodium. This should be particularly taken into account for those on a low salt diet (e.g. in some cases of congestive heart failure and renal impairment). Each 4 tablet dose contains 300 mg (7.5 mmol) of calcium. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. Treatment of children younger than 12 years of age is not generally recommended, except on medical advice. If symptoms persist, or treatment is required for more than 7 days continuously, medical advice should be sought. As with other antacid products, taking this product can mask the symptoms of other more serious, underlying medical conditions. This medicinal product contains aspartame (E951), a source of phenylalanine. May be harmful for people with phenylketonuria. This medicine contains Carmoisine lake (E122). This may cause allergic reactions.